Skip to main content

Table 2 Demographic and clinical characteristics of study subjects (N = 10,275)*

From: Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study

Characteristic

  

   Age, years

  

   < 18

1,114

(10.8)

   18-44

5,506

(53.6)

   45-54

2,176

(21.2)

   55-64

1,363

(13.3)

   ≥ 65

116

(1.1)

   Mean (SD)

37.7

(14.9)

Female

6,155

(59.9)

Comorbidities

  

   Mental disorders

  

Other anxiety disorders

1,813

(17.6)

Depressive disorders

3,885

(37.8)

Bipolar disorder

63

(0.6)

Tension headache

114

(1.1)

Personality disorders

101

(1.0)

Alcohol abuse/alcoholism

19

(0.2)

Drug abuse

132

(1.3)

Suicide attempts

97

(0.9)

   Sleep disorders

1,134

(11.0)

   Neoplasms

252

(2.5)

   Diabetes

396

(3.9)

   Migraine

414

(4.0)

   Ischemic heart disease

280

(2.7)

   Cerebrovascular disease

138

(1.3)

   Asthma

664

(6.5)

   Painful neuropathic disorders

964

(9.4)

   Symptoms, signs, and ill- defined conditions

  

Fatigue

1,690

(16.4)

Headache

974

(9.5)

Chest pain

1,431

(13.9)

Abdominal pain

1,552

(15.1)

Anxiety- related symptoms

1,627

(15.8)

Any symptoms, signs, and ill- defined conditions

4,692

(45.7)

Pretreatment healthcare costs, $

  

   Mean (SD)

4,812

(10,006)

   Median (IQR)

2,118

(896,4,975)

Region

  

   Northeast

3,165

(30.8)

   South

1,621

(15.8)

   West

1,858

(18.1)

   Midwest

3,631

(35.3)

Payer type

  

   HMO

2,971

(28.9)

   PPO

4,733

(46.1)

   Indemnity

554

(5.4)

   Other

283

(2.8)

  1. *Unless otherwise indicated, all values are number (%)
  2. GAD: Generalized anxiety disorder; SAD: Social anxiety disorder; HMO: Health maintenance organization; IQR: Interquartile range; PPO: Preferred provider organization; SD: Standard deviation